M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Outpatient Neutropenic Diet Study

Phase 2

Terminated

Conditions: Leukemia
Neutropenia

Interventions: Other: Raw Fruits & Vegetables
Other: Cooked Foods

First Posted Date: 2009-07-28

Last Posted Date: 2014-06-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00947648

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

Pomalidomide for Myelofibrosis Patients

Phase 2

Completed

Conditions: Polycythemia Vera
Thrombocythemia

Interventions: Drug: CC-4047
Drug: Prednisone

First Posted Date: 2009-07-24

Last Posted Date: 2019-06-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 70

Registration Number: NCT00946270

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Combining Varenicline and Bupropion for Smoking Cessation

Phase 3

Completed

Conditions: Smoking Cessation

Interventions: Drug: Varenicline
Other: Placebo
Drug: Bupropion
Behavioral: Counseling/Phone Calls

First Posted Date: 2009-07-22

Last Posted Date: 2021-12-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 641

Registration Number: NCT00943618

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations

Phase 1

Completed

Conditions: Acute Myelogenous Leukemia
Leukemia

Interventions: Drug: G-CSF
Drug: Plerixafor
Drug: Sorafenib

First Posted Date: 2009-07-22

Last Posted Date: 2017-03-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 33

Registration Number: NCT00943943

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

Phase 2

Completed

Conditions: Head And Neck Cancer

Interventions: Drug: Erlotinib
Drug: RAD001

First Posted Date: 2009-07-21

Last Posted Date: 2023-10-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 49

Registration Number: NCT00942734

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)

Phase 2

Terminated

Conditions: Leukemia
Pediatric Cancer

Interventions: Drug: Epratuzumab
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Mesna
Procedure: Infusion of NK cells
Drug: Interleukin-2

First Posted Date: 2009-07-20

Last Posted Date: 2014-05-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT00941928

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab

Phase 1

Completed

Conditions: Advanced Cancers

Interventions: Drug: HAI Oxaliplatin
Drug: 5-FU
Drug: Cetuximab
Drug: Bevacizumab
Drug: Leucovorin

First Posted Date: 2009-07-17

Last Posted Date: 2015-11-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 140

Registration Number: NCT00941499

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Enhanced Smoking Cessation for University Students

Not Applicable

Completed

Conditions: Current Every Day Smoker
Cigarette Smoker

Interventions: Other: Survey Administration

First Posted Date: 2009-07-17

Last Posted Date: 2018-11-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 39

Registration Number: NCT00941395

Locations: 🇺🇸
Texas A&M, College Station, Texas, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: GM-CSF (Sargramostim)
Drug: Rituximab

First Posted Date: 2009-07-16

Last Posted Date: 2018-09-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 130

Registration Number: NCT00940342

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Sirolimus and Cetuximab in Advanced Malignancies

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: Sirolimus
Drug: Cetuximab

First Posted Date: 2009-07-16

Last Posted Date: 2015-11-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 165

Registration Number: NCT00940381

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy